Cargando…

Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children

BACKGROUND: RTS,S/AS01, the leading malaria vaccine has been recommended by the WHO for widespread immunization of children at risk. RTS,S/AS01-induced anti-CSP IgG antibodies are associated with the vaccine efficacy. Here, the long-term kinetics of RTS,S/AS01-induced antibodies was investigated. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mugo, Robert M., Mwai, Kennedy, Mwacharo, Jedidah, Shee, Faiz M., Musyoki, Jennifer N., Wambua, Juliana, Otieno, Edward, Bejon, Philip, Ndungu, Francis M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641151/ https://www.ncbi.nlm.nih.gov/pubmed/34856981 http://dx.doi.org/10.1186/s12936-021-03961-2

Ejemplares similares

Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies
por: Mugo, Robert M., et al.
Publicado: (2023)

A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01 (E) on blood stage immunity in young Kenyan children
por: Ndungu, Francis M., et al.
Publicado: (2019)

A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E
por: Ndungu, Francis M., et al.
Publicado: (2012)

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01(E) and Protection against P falciparum Clinical Malaria
por: Olotu, Ally, et al.
Publicado: (2011)

Plasmodium falciparum-Specific Memory B-Cell and Antibody Responses Are Associated With Immunity in Children Living in an Endemic Area of Kenya
por: Jahnmatz, Peter, et al.
Publicado: (2022)

Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01(E) in Young Children
por: Olotu, Ally, et al.
Publicado: (2014)

Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01(E) on Blood Stage Immunity in Young Children
por: Bejon, Philip, et al.
Publicado: (2011)

Safety of the Malaria Vaccine Candidate, RTS,S/AS01(E) in 5 to 17 Month Old Kenyan and Tanzanian Children
por: Lusingu, John, et al.
Publicado: (2010)

Quantitative PCR Evaluation of Cellular Immune Responses in Kenyan Children Vaccinated with a Candidate Malaria Vaccine
por: Mwacharo, Jedidah, et al.
Publicado: (2009)

Malaria exposure drives both cognate and bystander human B cells to adopt an atypical phenotype
por: Aye, Racheal, et al.
Publicado: (2020)

Correction: Quantitative PCR Evaluation of Cellular Immune Responses in Kenyan Children Vaccinated with a Candidate Malaria Vaccine
por: Mwacharo, Jedidah, et al.
Publicado: (2011)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01(E) in 5 to 17 Month Old Kenyan and Tanzanian Children
por: Lusingu, John, et al.
Publicado: (2010)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01(E) in 5 to 17 Month Old Kenyan and Tanzanian Children
por: Lusingu, John, et al.
Publicado: (2010)

Clearance of Asymptomatic P. falciparum Infections Interacts with the Number of Clones to Predict the Risk of Subsequent Malaria in Kenyan Children
por: Liljander, Anne, et al.
Publicado: (2011)

The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
por: Fortpied, Juliette, et al.
Publicado: (2020)

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
por: Polhemus, Mark E., et al.
Publicado: (2009)

Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations
por: Nyagwange, James, et al.
Publicado: (2022)

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
por: Nadeem, Aroosa Younis, et al.
Publicado: (2022)

10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity
por: Addy, John W.G., et al.
Publicado: (2022)

The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan
por: Gosling, Roly, et al.
Publicado: (2016)

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children
por: Lievens, Marc, et al.
Publicado: (2011)

RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection
por: Enosse, Sonia, et al.
Publicado: (2006)

T Cell Responses to the RTS,S/AS01(E) and RTS,S/AS02(D) Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children
por: Ansong, Daniel, et al.
Publicado: (2011)

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial
por: Waitumbi, John N., et al.
Publicado: (2009)

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
por: White, Michael T, et al.
Publicado: (2015)

Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report
por: Merle, Corinne S.
Publicado: (2023)

Pooled testing conserves SARS-CoV-2 laboratory resources and improves test turn-around time: experience on the Kenyan Coast
por: Agoti, Charles N., et al.
Publicado: (2021)

Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi
por: Bell, Griffin J., et al.
Publicado: (2020)

Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?
por: Arora, Navneet, et al.
Publicado: (2021)

Should India be considering deployment of the first malaria vaccine RTS, S/AS01?
por: Rahi, Manju, et al.
Publicado: (2022)

RTS,S/AS01 Malaria Vaccine - The Next Step for a Developing Country
por: ZEHRA, ASMAT, et al.
Publicado: (2022)

RTS,S/AS01 malaria vaccine (Mosquirix(®)): a profile of its use
por: Syed, Yahiya Y.
Publicado: (2022)

Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review
por: Mumtaz, Hassan, et al.
Publicado: (2023)

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01(E) and RTS,S/AS01(B) Delayed Fractional Dose Regimens in Malaria-Naive Adults
por: Moon, James E, et al.
Publicado: (2020)

Individual-level variations in malaria susceptibility and acquisition of clinical protection
por: Valletta, John Joseph, et al.
Publicado: (2022)

The Ratio of Monocytes to Lymphocytes in Peripheral Blood Correlates with Increased Susceptibility to Clinical Malaria in Kenyan Children
por: Warimwe, George M., et al.
Publicado: (2013)

Simulated Impact of RTS,S/AS01 Vaccination Programs in the Context of Changing Malaria Transmission
por: Brooks, Alan, et al.
Publicado: (2012)

Induction of Plasmodium falciparum-Specific CD4(+) T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)
por: Agnandji, Selidji T., et al.
Publicado: (2011)

Randomized Controlled Trial of RTS,S/AS02(D) and RTS,S/AS01(E) Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
por: Owusu-Agyei, Seth, et al.
Publicado: (2009)

Correction: Randomized Controlled Trial of RTS,S/AS02(D) and RTS,S/AS01(E) Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
por: Owusu-Agyei, Seth, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_atlqhqt557j7osknabgehfpcfr